Shares in Spanish pharma group Grifols have plummeted after UK-based hedge fund Gotham City Research issued a report claiming it has fraudulently manipulated its financial reporting by not ...
The family that owns Spanish drugmaker Grifols and private equity firm Brookfield are considering whether to take the company private in a deal that could be worth around €5.5 billion (almost $6 ...
Grifols (GRFS) issued a statement to address certain information published in a media outlet on March 8, specifically a front-page article titled “The CNMV reveals to the judge ‘continuous ...
Immunoglobulin therapy improves mobility in phase 2/3 study Grifols has announced positive results from its phase 2/3 clinical trial evaluating the efficacy and safety of intravenous immunoglobulin ...
Grifols SA engages in the production of plasma derivatives. It operates through the following segments: Bioscience, Hospital, Diagnostic, Bio Supplies, and Others. The Bioscience Segment includes ...
Grifols expects to boost revenue and free cash flow, shares soar Spanish drugmaker Grifols said on Thursday it expects its revenue, core earnings and free cash flow to grow significantly in the ...
In this article, we are going to take a look at where Grifols, S.A. (NASDAQ:GRFS) stands against the other pharma stocks. The Rising Demand for Weight-Loss Medications and GLP-1 Developments ...
Muddy Waters CEO Carson Block picked Grifols (GRFS) as a short for the Robin Hood Foundation’s stock picking contest. However, said in an interview that Muddy Waters is “not actually short it ...
Upgrade your Yahoo Finance plan to get complete details for Grifols, S.A. Get advanced tools and insights to navigate the markets.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results